Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2023 - Issue
Submit an article Journal homepage
100
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants

Weimin Li1 Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6685-0161View further author information
ORCID Icon,
Sami Z Daoud2 Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USACorrespondence[email protected]
View further author information
,
Roopa Trivedi3 Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USAView further author information
,
Pradeep B Lukka4 Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Eulalia Jimenez5 Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, SpainView further author information
,
Eduard Molins5 Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, SpainView further author information
,
Catherine Stewart6 Statistics, Phastar, Chiswick, London, UKView further author information
,
Pranob Bharali3 Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA;7 BioPharmaceuticals R&D Late-Stage Development, AstraZeneca India Pvt Ltd., Bangalore, Karnataka, IndiaView further author information
&
Esther Garcia-Gil8 Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, SpainView further author information
 show all
Pages 2725-2735 | Received 07 Sep 2023, Accepted 07 Nov 2023, Published online: 26 Nov 2023

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease: 2022 report. Available from: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed August 8, 2023.
  • GBD 2017 Causes of Death Collaborators. Global, regional, and national age–sex–specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788. doi:10.1016/S0140-6736(18)32203-7
  • Zhu B, Wang Y, Ming J, Chen W, Zhang L. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353–1364. doi:10.2147/COPD.S161555
  • Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90–101. doi:10.3109/15412555.2012.661492
  • Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013;33(12):893–904. doi:10.1007/s40261-013-0138-1
  • Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830–836. doi:10.1183/09031936.00225511
  • AstraZeneca UK Ltd. Eklira genuair summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/eklira-genuair-epar-product-information_en.pdf. Accessed August 8, 2023.
  • Albertí J, Martinet A, Sentellas S, Salvà M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos. 2010;38(7):1202–1210. doi:10.1124/dmd.109.031724
  • Sentellas S, Ramos I, Albertí J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010;39(5):283–290. doi:10.1016/j.ejps.2010.01.004
  • Reisner C, Miller J, DePetrillo P, Maes A, Siddiqui S, Martin UJ. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. Pulm Pharmacol Ther. 2018;53:33–38. doi:10.1016/j.pupt.2018.09.005
  • Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:945–953. doi:10.2147/COPD.S154988
  • Fuhr R, Leselbaum A, Aubets J. Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: a phase 1, open-label, single-dose study. Clin Pharmacol Drug Dev. 2016;5(2):109–117. doi:10.1002/cpdd.209
  • Schmid K, Pascual S, Garcia Gil E, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther. 2010;32(10):1798–1812. doi:10.1016/j.clinthera.2010.09.002
  • Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther. 2012;25(2):193–199. doi:10.1016/j.pupt.2012.02.002
  • Jansat JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol. 2009;49(10):1239–1246. doi:10.1177/0091270009336353
  • Sahoo U. Basic principles. In: Clinical Research in Asia: Opportunities and Challenges. Cambridge: Woodhead Publishing Ltd; 2012:45–46.
  • DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298–1304. doi:10.7326/M22-1460

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.